ITK inhibition for the targeted treatment of CTCL

J Dermatol Sci. 2017 Jul;87(1):88-91. doi: 10.1016/j.jdermsci.2017.04.001. Epub 2017 Apr 3.

Authors

Itzel Bustos-Villalobos¹, Jennifer Williams Bergstrom¹, Nathan E Haigh¹, Jesus I Luna¹, Anupam Mitra¹, Alina I Marusina¹, Alexander A Merleev¹, Elizabeth A Wang¹, Andrea Sukhov¹, Hawa Sultani¹, Ruiwu Liu², Gaurav Bhardwaj², Wenchang Guo², Hsing-Jien Kung², Kit S Lam², Emanual Maverakis³

Affiliations

¹ Department of Dermatology, University of California, Davis, Sacramento, CA, USA.
² Department of Biochemistry and Molecular Medicine, University of California, Davis, Sacramento, CA, USA.
³ Department of Dermatology, University of California, Davis, Sacramento, CA, USA. Electronic address: emaverakis@ucdavis.edu.

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Agents / pharmacology*
Antineoplastic Agents / therapeutic use
Apoptosis / drug effects
Bcl-2-Like Protein 11 / metabolism
Cell Line, Tumor
Drug Screening Assays, Antitumor
Humans
Lymphoma, T-Cell, Cutaneous / drug therapy*
Lymphoma, T-Cell, Cutaneous / pathology
Molecular Docking Simulation
Protein Domains
Protein Kinase Inhibitors / chemistry
Protein Kinase Inhibitors / pharmacology*
Protein Kinase Inhibitors / therapeutic use
Protein-Tyrosine Kinases / antagonists & inhibitors*
Protein-Tyrosine Kinases / chemistry
Protein-Tyrosine Kinases / metabolism
Structure-Activity Relationship

Substances

Antineoplastic Agents
BCL2L11 protein, human
Bcl-2-Like Protein 11
Protein Kinase Inhibitors
Protein-Tyrosine Kinases
emt protein-tyrosine kinase

Grants and funding